KEGG pathway enrichment analysis suggests that ZHAST’s pharmacological mechanisms in OSAHS treatment may primarily involve pathways related to cancer, hepatitis B, the MAPK signaling pathway, AGE-RAGE signaling in diabetic complications, calcium signaling, and lipid and atherosclerosis pathways. Here, RENBP is linked to hepatitis B virus infection.